The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 versus Nelfinavir in Antiretroviral Therapy-Naive HIV-1-Infected Patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 1, 2004, Pages 22-32

  Rodriguez French, Amalia ^a   Boghossian, Jack ^b   Gray, Glenda E ^c   Nadler, Jeffrey P ^d   Quinones, Arnaldo R ^e   Sepulveda, Gladys E ^f   Millard, Judith M ^g   Wannamaker, Paul G ^g  

^a Ctro Vacunas/Tratamiento Enferm F   (Panama)

^b ST MICHAEL S MEDICAL CENTER   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e Comm Health Care/Center One Inc ^*  (United States)

^f Oregon Health and Science University   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

GW433908; HIV; NEAT; Nelfinavir

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; NELFINAVIR; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; ETHNOLOGY; FATIGUE; FEMALE; HEADACHE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSOMNIA; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; RACE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; VIRUS LOAD; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CARBAMATES; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NELFINAVIR; PHOSPHORIC ACID ESTERS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SULFONAMIDES;

EID: 0347990584     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200401010-00003     Document Type: Article

References (30)

1. Falcoz C, Jenkins JM, Bye C, et al. Pharmacokinetics of GW433908, a prodrug of APV, in healthy male volunteers. J Clin Pharmacol. 2002;42:887-898.
2. Wood R, Arasteh K, Stellbrink H-J, et al. A 6-week randomised controlled trial to compare the tolerability, pharmacokinetics and antiviral activity of GW433908 and amprenavir in HIV-1-infected patients. 2003;(In Press)
3. st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago.
4. Wire MB, Ballow C, Preston S, et al. Pharmacokinetics and satety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. 2003;(Submitted)
5. Maguire M, Shortino D, Klein A, et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agent Chemother 2002;46:731-738.
6. Maguire M, Guinea R, Griffin P, et al. Human immunodeficiency virus type 1 p1/p6 protease cleavage site changes at Gag positions L449 or P453 are linked to 150V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness. J Virol. 2002;76:7398-7406.
7. Data on file. Research Triangle Park, NC: GlaxoSmithKline.
8. Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report: US HIV and AIDS Cases Reported through December, 2000. 12:1-44. Available at: http://www.cdc.gov/hiv/stats/hasr1202.htm
9. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285;19:2486-2497.
10. Armstrong W, Calabrese L, Taege A. HIV update 2002: delaying treatment to curb rising resistance. Cleve Clin J Med. 2002;69:995-999.
11. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/. Accessed May 1, 2003.
12. nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego.
13. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
14. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/. Accessed January 28, 2000.
15. Johnson M, Beall G, Badley A, et al. ABT-378/ritonavir (ABT-378/R) versus NFV in antiretroviral naive subjects: week 48 comparison in a phase 111 blinded randomized clinical trial. AIDS. 2000;14(suppl 4):S7.
16. th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle.
17. Gartland M on behalf of the AVANTI Study Group. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus NFV in HIV-1-infected antiretroviral-naive patients. Antivir Ther. 2001;6:127-134.
18. th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco.
19. Munsliff AV, Brutus A, Elizee M. Switching dosing of NFV from TID to BID maintains virological efficacy. Antivir Ther. 1998;3(suppl 5): 51. Abstract 51.
20. th European Conference on Clinical Aspects and Treatment of HIV Infection; October 23-27, 1999; Lisbon.
21. th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego.
22. Bardsley-Elliot A, Plosker GL. NFV: an update on its use in HIV infection. Drugs. 2000;59:581-620.
23. Viracept (nelfinavir mesylate) [Product information]. La Jolla, CA: Agouron Pharmaceuticals: April 2003.
24. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603-1614.
25. Hernandez J, Cutrell A, Bonny T, et al. Diagnosis of abacavir hypersensitivity reactions among patients not receiving abacavir in two blinded studies. Paper presented at the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; July 8-11, 2003; Paris, France. Abstract 134.
26. Cutrell A, Hernandez J, Edwards M, et al. Clinical risk factor analysis of hypersensitivity reactions to abacavir: retrospective analysis of over 8,000 subjects receiving abacavir in 34 clinical trials. Paper presented at: 43rd Annual ICAAC; September 14-17, 2003; Chicago, IL. Abstract H-2013)
27. Fung HB, Kirschenbaum HL, Hameed R. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000;22:549-572.
28. Noble S, Goa KL. Amprenavir: a review of its clinical potential in patients with HIV infection. Drugs. 2000;60:1383-1410.
29. th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston.
30. International AIDS Society-USA. Drug resistance in HIV-1 update. Top HIV Med. 2002;10:11-15.